Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy and Hormone Therapy With SpaceOAR TM for Patients With High - Risk Localized Prostate Cancer (DESAR-H)

Inclusion Criteria:

1. Histopathologically confirmed prostate adenocarcinoma within 6 months of study enrollment
2. Patients with prostate cancer at high risk or above (c T3a-T4 or grade group 4-5 or PSA \> 20 n g/mL) )
3. Patients who have undergone or are scheduled to undergo hormone therapy for high-risk prostate cancer
4. Adults over 20 years of age
5. Whole body performance ECOG 0-1
6. SpaceOAR Patients who consented to the procedure and study

Exclusion Criteria:

1. prostate removal surgery, Patients with a history of lower pelvic surgery including rectal cancer surgery
2. primary cancer Patients with posterior extracapsular extension
3. Medically biodegradable substances such as bleeding predisposition Patients for whom infusion is not appropriate
4. Patients with a history of previous pelvic radiation therapy
5. Patients with lymph node metastasis or distant metastasis